Mice with pancreatic cancer treated with a combination of cannabidiol (CBD) and chemotherapy survived nearly three times longer than those treated with chemotherapy alone, according to a new study that spotlights the potential for human treatment.
CBD, the non-psychoactive (non-intoxicating) compound in marijuana, has already been shown to improve side effects of chemotherapy like nausea and vomiting. The latest results provide more justification for testing in humans, building on prior animal research that uncovered possible anti-cancer properties of the compound.
“Cannabidiol is already approved for use in clinics [in the UK], which means we can quickly go on to test this in human clinical trials,” said lead researcher Marco Falasca from Queen Mary University of London.
While human trials involving CBD as a cancer treatment may move faster in the UK, similar efforts could face obstacles in the U.S., where CBD derived from marijuana is still considered an illegal (Schedule 1) substance under federal law. Progress is being made, however, with the US FDA approving the first drug comprised of CBD to treat severe forms of epilepsy in June of this year.
Pancreatic cancer is among the deadliest forms of cancer in the world in terms of overall survival rates. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is just under 7%. It’s the 12th most common cancer globally, with the highest incidence occuring in
